title: Osteocalcin, cortisol levels, and bone mineral density in prepubertal children with asthma treated with long-term fluticasone propionate.
abstract: OBJECTIVE
  The objective of this study is to determine the effects of the long-term treatment with inhaled fluticasone propionate on osteocalcin, cortisol levels, and bone mineral status in children with asthma.
  
  
  METHODS
  This cross-sectional study examined 230 prepubertal children with asthma (aged 6–11) who had intermittently used inhaled fluticasone propionate for at least 5 years at a mean daily dose of 200 μg (range: 200-350 μg). Serum osteocalcin, cortisol, and bone mineral density (BMD) of the lumbar spine were obtained from each participant. The control group consisted of gender- and age-matched children (n = 170) who were newly diagnosed with asthma and who were not being treated with corticosteroid.
  
  
  RESULTS
  The average age (± SEM) was 8.9 ± 0.7 years, their mean (± SEM) daily steroid dose was 180.3 ± 55.0 μg, with 236.5 ± 17.2 g total steroid use during treatment. Between the study and the control groups, no significant differences were observed in cortisol, osteocalcin levels, and BMD (p > 0.05).
  
  
  CONCLUSIONS
  Long-term treatment with inhaled fluticasone propionate (100 μg twice daily) revealed no negative effects on serum osteocalcin, cortisol levels, and BMD in children with asthma.
authors: Division of Pediatric Allergy, Bezmialem Vakif University, Istanbul, Turkey. minozkaya@yahoo.com
authors: Emin
authors: E
authors: Ozkaya
authors: Mustafa A
authors: MA
authors: Nursoy
authors: Selcuk
authors: S
authors: Uzuner
authors: Ufuk
authors: U
authors: Erenberk
authors: Erkan
authors: E
authors: Çakır
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015519:Bone Density / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D015675:Osteocalcin / Q000097:blood*; D011627:Puberty / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D015675:Osteocalcin; D000068298:Fluticasone; D006854:Hydrocortisone